Revenue
No reported data
MBX Biosciences, Inc. (MBX)
Price—Loading quote
Net income
2023
2024
2025
Free cash flow
2023
2024
2025
Total cash / debt
CashTotal debt
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Research & development | $79.2M | $57.4M | $28.5M |
| Operating expenses | $98.1M | $68.2M | $35.3M |
| Operating income | −$98.1M | −$68.2M | −$35.3M |
| Net income | −$87.0M | −$61.9M | −$32.6M |
| Basic EPSper diluted share | -$2.38 | -$5.82 | -$31.96 |
| Diluted EPSper diluted share | -$2.38 | -$5.82 | -$31.96 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 8, 2026Form 4 · 10b5-1 | Azoulay SalomonChief Medical Officer | SellCommon Stock | 15.0K | $38.30 | $574.6K | 14.8K |
| May 8, 2026Form 4 · 10b5-1 | Azoulay SalomonChief Medical Officer | SellCommon Stock | 55.0K | $38.38 | $2.11M | 14.8K |
| May 6, 2026Form 4 | Azoulay SalomonChief Medical Officer | SellCommon Stock | 231 | $29.54 | $6.8K | 14.8K |
| May 6, 2026Form 4 | Hawryluk P. KentPresident & CEO | SellCommon Stock | 607 | $29.54 | $17.9K | 727.7K |
| Mar 13, 2026Form 4 | Hawryluk P. KentPresident & CEO | BuyCommon Stock · indirect | 18.5K | $28.41 | $525.6K | 486.8K |